Zealand Pharma Survodutide posts 16.6% weight loss, shows lean mass preservation
Zealand announced that its partner Boehringer Ingelheim has reported topline results from the phase 3 (SYNCHRONIZE-1) trial of survodutide (GLP-1/glucagon analog) in adults with overweight/obesity without T2D. The 16.6% weight loss at 76 weeks achieved with survodutide in the phase 3 trial appears lower than the 18.7% that the drug achieved in phase 2 at 46 weeks. This outcome places survodutide somewhere between semaglutide and tirzepatide when it comes to weight loss efficacy, however, we're impressed to learn that body weight reduction with survodutide was driven predominantly by loss of fat tissue, with lean mass contributing only a small proportion of total weight. We look forward to seeing the full dataset at ADA in June 2026. DKK 500 and Accumulate maintained.Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.